US equities
|
META
$620.19
▼-1.64%
MU
$928.76
▲+2.77%
NVDA
$217.94
▲+0.90%
TSLA
$407.46
▲+4.04%
SPCX
$148.58
▲+1.14%
AAPL
$347.10
▲+0.93%
AMD
$560.26
▲+5.45%
MSFT
$531.33
▼-0.24%
META
$620.19
▼-1.64%
MU
$928.76
▲+2.77%
NVDA
$217.94
▲+0.90%
TSLA
$407.46
▲+4.04%
SPCX
$148.58
▲+1.14%
AAPL
$347.10
▲+0.93%
AMD
$560.26
▲+5.45%
MSFT
$531.33
▼-0.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Surmodics, Inc.
< Previous
1
2
Next >
Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance
November 08, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15
November 07, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium
November 07, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device Applications
October 31, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics to Report Fourth Quarter and Fiscal 2023 Financial Results on November 8
October 10, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics to Participate in Upcoming Investor Conferences in August
August 09, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
August 02, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics to Report Third Quarter of Fiscal 2023 Financial Results on August 2
July 12, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon
June 20, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics Receives FDA 510(k) Clearance for Pounce™ LP Thrombectomy System
June 14, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics to Participate in the Jefferies Healthcare Conference on June 8
May 25, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
April 26, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics Announces First Patient Enrolled in PROWL Registry Study Using the Pounce™ Thrombectomy System
April 20, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics to Report Second Quarter of Fiscal 2023 Financial Results on April 26
April 19, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics Announces Successful First Patient Use of Sublime™ Radial Access Microcatheter Designed for the Periphery
April 19, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics to Participate in the 22nd Annual Needham Virtual Healthcare Conference on April 20
April 11, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics Provides Regulatory Update on its Strategy to Submit an Amended Premarket Approval Application for the SurVeil™ Drug-Coated Balloon
March 28, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics to Participate in Upcoming Investor Conferences in March
March 08, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics Reports First Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
February 06, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics to Host Virtual Annual Meeting of Shareholders
January 31, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics to Report First Quarter of Fiscal 2023 Financial Results on February 6
January 26, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Differentiated Capabilities of Surmodics’ Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET Conference
January 19, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil™ Drug-Coated Balloon
January 19, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18
January 16, 2023
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposium
November 17, 2022
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics Announces SWING Trial 12-Month Data to be Presented at VEITHsymposium on November 16
November 11, 2022
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics Reports Fourth Quarter and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Financial Guidance
November 09, 2022
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
24-Month Data from Surmodics’ TRANSCEND Trial Presented at VIVA 2022 Conference
November 02, 2022
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on November 9th
October 28, 2022
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
Surmodics Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022
October 26, 2022
From
Surmodics, Inc.
Via
Business Wire
Tickers
SRDX
< Previous
1
2
Next >
